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Abstract
Background: Altered plasma levels of protein C, thrombomodulin, and the endothelial protein C receptor
are associated with poor clinical outcomes in patients with acute respiratory distress syndrome (ARDS). We
hypothesized that common variants in these genes would be associated with mortality as well as ventilator-free
and organ failure-free days in patients with ARDS.
Methods: We genotyped linkage disequilibrium-based tag single-nucleotide polymorphisms in the ProteinC,
Thrombomodulin and Endothelial Protein C Reptor Genes among 320 self-identified white patients of European
ancestry from the ARDS Network Fluid and Catheter Treatment Trial. We then tested their association with mortality
as well as ventilator-free and organ-failure free days.
Results: The GG genotype of rs1042580 (p = 0.02) and CC genotype of rs3716123 (p = 0.002), both in the
thrombomodulin gene, and GC/CC genotypes of rs9574 (p = 0.04) in the endothelial protein C receptor gene were
independently associated with increased mortality. An additive effect on mortality (p < 0.001), ventilator-free
days (p = 0.01), and organ failure-free days was observed with combinations of these high-risk genotypes. This
association was independent of age, severity of illness, presence or absence of sepsis, and treatment allocation.
Conclusions: Genetic variants in thrombomodulin and endothelial protein C receptor genes are additively
associated with mortality in ARDS. These findings suggest that genetic differences may be at least partially
responsible for the observed associations between dysregulated coagulation and poor outcomes in ARDS.
Background
Acute respiratory distress syndrome (ARDS) is a common
cause of respiratory failure characterized by acute pulmonary
edema and lung inflammation [1]. ARDS occurs in both adults
and children and has an incidence of approximately 200,000
patients per year in the United States. Estimates of mortality
range from 18 % to 58 % [2, 3]. The majority of deaths among
patients with ARDS are attributed tomultiorgan failure [1, 4].
A number of experimental and human studies suggest
that excessive activation of coagulation is associated
with increased mortality in patients with ARDS [5–11].
Activated protein C (PC) is an endogenous regulator
of coagulation that has both anticoagulant and anti-
inflammatory effects [12, 13]. Protein C is activated
by thrombin in the presence of thrombomodulin (TM),
and membrane-bound endothelial protein C receptor
(EPCR) potentiates this activation [14]. Human lung
epithelial cells express protein C, EPCR, and TM, and the
lung epithelium can actively modulate the protein C path-
way [15]. Alterations in plasma levels of protein C, TM,
and soluble EPCR are associated with increased mortality
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and greater severity of illness among patients with ARDS
[13, 16–18]. It is unclear if these alterations and their asso-
ciations with clinical outcomes are determined exclusively
by environmental factors that precipitate ARDS, such as
the virulence of the infection, the extent of aspiration, and
the severity of shock, or whether they are also influenced
by genetic variation.
Common genetic variation (e.g., polymorphisms with
minor allele frequency >5 %) in the genes encoding for
PC, EPCR, and TM has been well-characterized and is
associated with adverse clinical outcomes in disorders
such as sepsis and cardiovascular disease [19–29]. Since
the genetics of diseases such as ARDS are likely complex
and therefore likely to involve several low-penetrance
loci [30, 31], analyzing multiple variants of genes encod-
ing components of the same physiological cascade may
prove to be a more powerful approach than studies of
single candidates [32–35]. We hypothesized that com-
mon genetic variations in the genes encoding for protein
C, EPCR, and TM are associated with adverse clinical
outcomes in patients with ARDS. We also hypothesized
that variants in each individual gene may each have a
small effect and that a combination of these variants
would be associated with adverse clinical outcomes.
Methods
Study population
The study population included subjects enrolled in the
ARDS Network Fluid and Catheter Treatment Trial
(FACTT) from whom DNA was available. FACTT was a
multicenter trial in which researchers compared conserva-
tive and liberal strategies of fluid management using explicit
protocols applied for 7 days in patients with ARDS [36, 37].
Participants were also randomly assigned to receive either a
pulmonary arterial catheter or a central venous catheter in
a two-by-two factorial design [36]. All patients were venti-
lated using a lung-protective ventilation strategy. The pri-
mary outcome was mortality at 60 days [36, 37].
As part of the primary enrollment in the FACTT trial,
patients were also asked to co-enroll in an ancillary
study designed to study the role of genetic biomarkers.
Patients who consented to participate in the ancillary
study had additional whole blood collected, from
which DNA was extracted. DNA was extracted and
made available for this study by the ARDS Network
DNA repository in the Center for Human Genetics
Research at Vanderbilt University (Nashville, TN,
USA). DNA was available from 470 patients, 320 of
whom were of self-identified white race of European
ancestry. We limited the present analysis to white patients
of European ancestry to avoid confounding due to popula-
tion stratification.
The institutional review boards of each participating
hospital reviewed and approved the primary and ancillary
studies. Written informed consent was obtained from
participants or their legally authorized surrogates.
Outcome measures
The primary outcome measure was mortality at 60 days. The
secondary outcome measures were (1) the number of
ventilator-free days (VFDs) [38] and (2) the number of organ
failure-free days during the first 28 days of hospitalization [36].
Single-nucleotide polymorphism selection and genotyping
To comprehensively characterize all the common genetic
variation in these genes, we genotyped linkage disequilib-
rium (LD)-based single-nucleotide polymorphisms (tag
SNPs) in the genomic region and 2000 bp upstream and
downstream in the PC, EPCR, and TM genes. We used
the resequencing data on these genes available from the
Seattle SNPs website (http://snp.gs.washington.edu/Seat-
tleSeqAnnotation144/) and selected tag SNPs using MUL-
TIPOP software [39] with minimum allele frequency set
at 5 % and r2 set at 0.8.
SNPs were genotyped using three commercially
available technologies according to the manufacturers’
instructions: Illumina Golden Gate 384-plex (Illumina,
San Diego, CA, USA), GenomeLab SNPstream 48-plex
(Beckman Coulter, Brea, CA, USA), and template-directed
primer extension with fluorescence polarization detection
using the AcycloPrime II kit (PerkinElmer, Waltham, MA,
USA) [40]. Primer sequences are available upon request.
Samples were arrayed on 96-well plates with negative and
positive controls (duplicates) on each plate. Investigators
blinded to the clinical status scored the genotypes.
Data analysis
Nonpolymorphic SNPs and SNPs with minor allele
frequency <5 % were removed from the analysis. All
analyzed SNPs were tested and found to be in Hardy-
Weinberg equilibrium. We assessed genotypic effects at
single SNP loci in each of the three genes using the χ2
test to compare the associations of genotypes with
60-day mortality. In the univariate analysis of individ-
ual SNP genotypes, additive, dominant, and recessive
models were considered. Next, we used multivariate
logistic regression, incorporating the associated SNPs
in a single multivariate model to assess if each SNP
was independently associated with mortality when
tested with other SNPs in the same gene. We included
age, presence of nonpulmonary sepsis, fluid management
strategy, and Acute Physiology and Chronic Health Evalu-
ation (APACHE) score as covariates in the model because
of their previously reported association with clinical out-
comes in patients with ARDS. We corrected for multiple
comparisons for the multiple SNPs genotyped within each
gene by using multiple permutations as implemented in
PLINK [41].
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SNPs from each gene with an independent effect on
mortality were retested in a logistic regression model with
the covariates mentioned above and all SNPs with a statis-
tically significant association with outcome. We also con-
ducted an exploratory analysis, testing for a haplotype
effect. Haplotype frequencies in each gene were estimated
from unphased genotype data using the PHASE algorithm
in Haploview, and the association of the imputed haplo-
types on mortality was assessed using a case-control
approach as implemented in Haploview [42, 43].
We examined the joint effect of a combination of
these “high-risk genotypes” associated with mortality on
clinical outcomes. For the purpose of this analysis, we
defined the following genotypes with an independent
effect on mortality as high-risk genotypes:
1. CC genotype of the rs3176123 SNP in the TM gene
2. GG genotype of the rs1042580 SNP in the TM gene
3. GC/GG genotypes of the rs9574 SNP in the EPCR
gene
The association of combinations of genotypes with out-
comes was assessed using the Cochran-Armitage trend
test to compare clinical outcomes across categories of
patients stratified by the number of high-risk genotypes
possessed by each individual. We used regression models
to adjust for age, severity of illness (APACHE), presence
of sepsis, and allocation to treatment arm. In addition,
given the a priori hypothesis that all three genes in
the protein C pathway (i.e., protein C, EPCR, and
TM) would have an effect on mortality in patients with
ARDS, we conducted an additional analysis with the
rs1799810 SNP of the protein C gene included in the
combined model.
All analyses were carried out using Stata 9 (StataCorp,
College Station, TX, USA), PLINK [42], and Haploview
[43, 44] software. On the basis of an assumption of mini-
mum allele frequency of 5 % and a dominant model, the
sample size of 320 patients has a power of 80 % to detect
an increase in mortality by a relative ratio of 2.1 or
greater at p < 0.05.
Results
The baseline characteristics of the self-identified white
patients of European ancestry enrolled in the FACTT
trial stratified by the 320 for whom DNA was available
and the 321 for whom DNA was not available are
depicted in Table 1. The baseline characteristics of the
study population are similar to the white patients of
European ancestry in the FACTT trial for whom DNA
was not available. Genotype frequencies of the assayed
SNPs in the protein C, EPCR, and TM genes and the fre-
quencies stratified by mortality at 60 days are depicted in
Tables 2, 3 and 4.
In the EPCR gene, the GC/GG genotypes of the
rs9574 SNP were associated with higher mortality (24 %
vs. 11 %) compared with the CC genotype (p = 0.04 after
correction for multiple SNPs tested in the EPCR gene).
Two other SNPs in the EPCR gene—rs2069952 and
rs2069948—that were highly correlated with rs9574
(r2 = 0.95), were also associated with mortality at 60 days;
however, when tested in a regression model that included
these two SNPs and rs9574, only rs9574 retained the asso-
ciation with mortality, suggesting that the effect was not
independent of the effect of the rs9574 SNP. The associ-
ation of the rs9574 SNP with mortality was independent
of age, severity of illness, sepsis as the primary cause of
ARDS, and the fluid management arm (Table 5).
Two SNPs in the TM gene were independently associ-
ated with mortality at 60 days. The CC genotype of the
rs3176123 SNP was associated with higher mortality
(57 % vs. 20 %) compared with the AC/CC genotypes
(p = 0.002 corrected for multiple SNPs tested). The GG
genotype of the rs1042580 SNP was also associated with
Table 1 Characteristics of patients from the Fluid and Catheter
Treatment Trial
Variable Caucasians with
DNA (n = 320)
Caucasians without
DNA (n = 321)
p Value
Age, years, mean ± SD 50 ± 16 52 ± 16 0.06
Male sex, % 51 % 51 % 0.96
APACHE III score,
mean ± SD




Pneumonia, % 46 % 47 % 0.78
Trauma, % 8 % 5 % 0.15
Sepsis, % 21 % 25 % 0.26
Multiple transfusions, % 2 % 1 % 0.25
Aspiration, % 17 % 17 % 0.90
Baseline PaO2/FiO2 103 ± 48 106 ± 49 0.45
Severity of ARDS 0.36
Mild 59 % 53 %
Moderate 36 % 41 %
Severe 5 % 6 %
Day 1 PIP 32 ± 8 32 ± 9 0.32
Day 1 PEEP 9.4 ± 4 9.5 ± 4 0.7
Fluid management,
liberal, %
48 % 55 % 0.09
Mortality at 60 days, % 21 % 25 % 0.19
Ventilator-free days,
median (range)
19 (0–28) 17 (0–28) 0.22
APACHE Acute Physiology and Chronic Health Evaluation, ARDS acute respiratory
distress syndrome, FiO2 fraction of inspired oxygen, PaO2 partial pressure of
arterial oxygen, PEEP positive end-expiratory pressure, PIP peak
inspiratory pressure
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higher mortality (35 % vs. 19 %) compared with the AG/
AA genotypes (p = 0.02 corrected for multiple SNPs
tested). These two SNPs had limited correlation with each
other (r2 = 0.14), and both SNPs were independently
associated with mortality when analyzed in a joint lo-
gistic regression model including the two SNPS and
age, presence of non-pulmonary sepsis, APACHE score,
and allocation to fluid management strategy (Table 5).
The association of the rs3176123 and rs1042580 SNPs
with mortality was independent of age, severity of ill-
ness, sepsis, and the fluid management arm (Table 5).
Of the protein C SNPs analyzed, the AA genotype of
the rs1799810 SNP showed a trend toward increased
mortality (26 % vs. 19 %) compared with the TT/AT
genotypes, but this trend was not statistically signifi-
cant (p = 0.18).
We tested the effect of a combination of these un-
favorable SNPs on mortality at 60 days in a joint logistic
regression model. On the basis of their biological inter-
action in a common pathway, we hypothesized that mul-
tiple unfavorable SNPs would have a more significant
impact on the protein C pathway and therefore would
be associated with increased mortality. The CC genotype
of the rs3176123 SNP, the GG genotype of the rs1042580
SNP in the TM gene, and the GC/CC genotypes of rs9574
SNP in the EPCR gene were independently associated
with mortality at 60 days. This association was inde-
pendent of age, severity of illness, sepsis, and the fluid
management arm (Table 5). We also examined mortality
at 60 days among patients stratified by the number of
high-risk genotypes possessed by each individual. There
was an increase in mortality at 60 days with the presence
of each additional high-risk genotype: 5.8 % [1.2–16.2],
20 % [15–26], and 41 % [27–57] (p < 0.001) (Fig. 1). The
association was independent of age, severity of illness,
sepsis, and the fluid management arm.
The number of VFDs was also compared among pa-
tients stratified by the number of high-risk genotypes
carried by each individual. There was a decrease in the
number of VFDs with the presence of each additional
high-risk genotype (p = 0.01) (Fig. 2). This association was
also independent of age, severity of illness, sepsis, and the
fluid management arm.
The number of coagulation, renal, cardiovascular, and
central nervous system organ failure-free days was
compared among patients stratified by the number of
high-risk genotypes carried by each individual. There
was also a decrease in the number of coagulation, renal,
cardiovascular, and central nervous system organ failure-
free days with the presence of each additional high-risk
genotype (Fig. 3).
Given our a priori hypothesis that genetic heterogen-
eity in all three genes (protein C, EPCR, and TM) in this
pathway would have an effect on mortality in patients
with ARDS, we conducted an additional analysis with
four SNPs in the model: the three SNPs that are inde-
pendently associated with mortality at 60 days and a
fourth, the rs1799810 SNP in the protein C gene that
had a trend toward increased mortality which did not
Table 2 Genotype counts of protein C tag single-nucleotide










rs1158867 C T 8/23/19 32/91/55 0.34
rs1799808 T C 9/31/25 27/105/117 0.21
rs1799810 T A 10/31/26 47/129/76 0.17
rs2069901 G A 10/31/26 46/128/78 0.22
rs2069904 A G 7/26/34 31/108/114 0.40
rs2069910 A G 16/29/22 51/112/87 0.53
rs2069912 G A 6/25/36 23/99/129 0.73
rs2069914 A G 6/25/36 22/100/129 0.73
rs2069916 A G 9/31/27 26/104/118 0.26
rs2069918 A G 5/23/39 17/86/149 0.83
rs2069920 G A 14/29/24 36/116/97 0.19
rs2069924 A G 9/32/26 27/106/116 0.25
rs2069928 A C 3/21/43 10/72/168 0.64
rs2069931 A G 10/29/28 31/106/114 0.50
rs2069933 A G 8/29/30 35/102/115 0.67
rs5937 G A 7/26/34 26/109/117 0.52
rs908787 G C 1/4/62 3/25/224 0.46
rs971207 A G 7/30/30 35/104/112 0.45
dbSNP ID single-nucleotide polymorphism database identifier
aGenotype counts (minor homozygotes/heterozygotes/major homozygotes)
Table 3 Genotype counts of endothelial protein C receptor tag single-nucleotide polymorphisms among survivors and nonsurvivors
dbSNP ID Allele 1 Allele 2 Genotype countsa (survivors) Genotype countsa (nonsurvivors) p Value (uncorrected) p Valueb (corrected)
rs2069948 G A 8/40/19 58/116/75 0.05 0.07
rs2069951 A G 0/7/60 0/24/229 0.76 1
rs2069952 G A 7/40/19 58/116/77 0.03 0.05
rs867186 G A 0/8/59 0/47/205 0.18 0.4
rs9574 C G 7/38/19 58/111/75 0.02 0.04
dbSNP ID single-nucleotide polymorphism database identifier
aGenotype counts (minor homozygotes/heterozygotes/major homozygotes)
bp Value (corrected) is corrected for multiple SNPs tested within the endothelial protein C receptor gene
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achieve statistical significance. Even though the protein
C SNP rs1799810 individually did not have a statistically
significant association with mortality, we found that the
mortality increased from 10.3 % [2.2–27.3] for those
with no high-risk SNPs vs. 15.2 % [9.9–21.7], 28.5 %
[19.8–38.5], and 63.6 % [30.8–89.1] for those with one,
two, and three high-risk SNPs, respectively. Those with
greater numbers of high-risk SNPs had fewer VFDs and
fewer organ failure-free days (see Additional file 1). We
did not find any joint haplotype effect on either the
primary or secondary outcomes in any of these three
genes.
Thrombomodulin SNPs and plasma levels
Plasma levels of soluble TM were higher among individ-
uals carrying the GG genotype of the rs1042580 SNP
(median 106 ng/ml, interquartile range 75–187 ng/ml)
as compared with the individuals with the AG and AA
genotypes (median 90 ng/ml, interquartile range 59–
141 ng/ml) (p < 0.05). The plasma TM levels among in-
dividuals with the CC genotype of the rs3176123 SNP
(median 94 ng/ml, interquartile range 53–148 ng/ml)
did not have a statistically significant difference from the
individuals carrying the AC and CC genotypes (median
93 ng/ml, interquartile range 61–149 ng/ml) (p = 0.85).
EPCR SNPs and plasma levels
Plasma levels of soluble EPCR were higher among indi-
viduals carrying the GG genotype of rs9574 SNP (me-
dian 66.1 ng/ml, Interquartile range 45–104 ng/ml) as
compared with the individuals with the AG and AA ge-
notypes (median 88.5 ng/ml, interquartile range 56–
133 ng/ml) (P < 0.01).
To test whether the effect of the SNPs of the rs1042580
was mediated via plasma TM levels, we first tested the as-
sociation of rs1042580 with mortality in a logistic regres-
sion model and then added plasma TM levels to the
regression model. With addition of plasma TM to the re-
gression model, the odds of mortality decreased slightly
from 2.32 (95 % CI 1.06–5.1, p < 0.04) to 2.15 (95 % CI
0.93–4.9, p = 0.07), suggesting that plasma TM levels are
at most a minor part of the effect of the SNP on mortality.
To test whether the effect of the SNPs of the rs9574
was mediated via plasma soluble Endothelial Protein C
Receptor (sEPCR) levels, we tested the association of
rs9574 with mortality in a logistic regression model and
then added plasma EPCR as a mediator in the regression
model. With addition of plasma sEPCR to the regression
model, the odds of mortality decreased from 2.53 (95 %
Table 4 Genotype counts of thrombomodulin tag single-nucleotide polymorphisms among survivors and nonsurvivors
dbSNP ID Allele 1 Allele 2 Genotype countsa (nonsurvivors) Genotype countsa (survivors) p Value (uncorrected) p Valueb (corrected)
rs1042580 G A 17/29/21 32/127/93 0.010 0.02
rs1962 G A 2/20/45 19/85/149 0.18 0.39
rs2007363 A C 1/18/48 15/77/161 0.14 0.26
rs3176118 O X 1/9/55 2/45/204 0.58 1
rs3176123 C A 8/11/48 6/76/169 0.0001 0.002
dbSNP ID single-nucleotide polymorphism database identifier
aGenotype counts (minor homozygotes/heterozygotes/major homozygotes)
bp Value (corrected) is corrected for multiple SNPs tested within thrombomodulin gene
Table 5 Multivariate logistic regression model with mortality at
60 days as the outcome and genotypes as predictors
Predictors OR 95 % CI p Value
Endothelial protein C receptor (EPCR) SNPs
rs9574, GC/GG vs. CC 2.8 1.1–7.3 0.04
Age, years 1.03 1.01–1.05 <0.003
APACHE III score 1.04 1.02–1.05 <0.001
Sepsis, yes/no 1.3 0.6–2.7 0.6
PaO2/FiO2 1.001 0.99–1.01 0.7
Fluid strategy, liberal vs. conservative 1.5 0.8–2.8 0.24
Thrombomodulin (TM) SNPs
rs3176123, CC vs. AA/AC 6.3 1.6–24.8 0.008
rs1042580, GG vs. AA/AG 2.8 1.2–6.1 <0.02
Age, years 1.02 1.00–1.05 0.03
APACHE III score 1.04 1.02–1.05 <0.001
Sepsis, yes/no 1.2 0.6–2.3 0.55
PaO2/FiO2 1.001 0.99–1.01 0.15
Fluid strategy, liberal vs. conservative 1.2 0.6–2.3 0.88
Thrombomodulin, endothelial protein C receptor and protein C SNPs
(combined model)
THBD rs3176123 6.1 1.6–24 0.01
THBD rs1042580 2.6 1.1–6.1 0.03
EPCR rs9574 2.9 1.08–7.9 0.03
Age, years 1.03 1.0–1.05 <0.02
APACHE III score 1.04 1.01–1.05 <0.001
Sepsis, yes/no 1.3 0.6–2.7 0.53
PaO2/FiO2 1.00 0.99–1.01 0.71
Fluid strategy, liberal vs. conservative 1.3 0.6–2.6 0.44
APACHE Acute Physiology and Chronic Health Evaluation, EPCR endothelial
protein C receptor, FiO2 fraction of inspired oxygen, PaO2 partial pressure of
arterial oxygen, SNP single-nucleotide polymorphism, THBD thrombomodulin
gene, TM thrombomodulin
Models are adjusted for age, APACHE III score, presence of sepsis, baseline
PaO2/FiO2 ratio, and allocation to fluid management arm
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CI 1.1–5.8, p < 0.03) to 2.23 (95 % CI 0.96–5.2, p = 0.06),
again suggesting that soluble Endothelial Protein C
Receptor (EPCR) mediates a minor part of the effect of
the rs9574 SNP on mortality.
Discussion
The results of this study indicate that common genetic
variations in the protein C pathway are associated with
adverse clinical outcomes in adult patients with ARDS.
The GC/CC genotypes of the rs9574 SNP in the EPCR
gene, as well as the GG genotype of the rs1042580 SNP
and the CC genotype of the rs3176123 SNP, both in the
TM gene, were independently associated with mortality
in ARDS. We also found that a combination of these
high-risk genotypes had an additive effect on mortality,
ventilator-free days, and organ failure-free days in ARDS.
However, the effect of SNPs was not mediated via their
effect on the levels of soluble TM or EPCR in plasma,
suggesting the SNPs may have their effect through other
mechanisms related to altered functioning of these
molecules. This finding has major implications for
current understanding of the pathogenesis of ARDS.
Abnormalities of the coagulation pathway and its regula-
tory proteins and the association of these abnormalities
with clinical outcomes in patients with ARDS have been
described previously [6–11]. However, these abnormal-
ities were thought to be due largely to environmental
factors (e.g., severity of illness, virulence of organisms,
severity of lung injury). The present findings suggest that
genetic susceptibility may contribute to this dysregulated
coagulation and the poor clinical outcomes in patients
with ARDS.
Both intraalveolar and systemic coagulation are acti-
vated in patients with ARDS [8–10, 44]. Although
intraalveolar fibrin deposition may have beneficial effects
on gas exchange by sealing leakage sites and compart-
mentalizing infection, excessive fibrin deposition can be
harmful because it can activate neutrophils and fibro-
blasts, compromise endothelial integrity, contribute to a
loss of surfactant activity, decrease alveolar fluid
clearance, and induce thrombotic obstruction of the
microcirculation [6, 7]. The injury to the pulmonary
microcirculation via inflammatory and thrombotic



















Number of  High Risk Genotypes
Fig. 1 Patients are stratified on the basis of the number of high-risk genotypes possessed by each individual, and the height of the bars
represents 60-day mortality in each group. There is a stepwise increase in mortality with increasing number of high-risk genotypes: none 5.8 %



























Number of High Risk Genotypes
Fig. 2 Patients are stratified on the basis of the number of high-risk genotypes possessed by each individual, and the height of the bars
represents the number of ventilator-free days in each group. There is a stepwise decrease in the number of ventilator-free days with increasing
number of high-risk genotypes (p = 0.02)
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pulmonary dead space fraction that is an independent
predictor of mortality in ARDS [45]. In addition, sys-
temic activation of coagulation may also contribute to
hypercoagulability and the development of multiorgan
failure with widespread microvascular thrombus forma-
tion [1, 4, 17].
Activated protein C is an endogenous regulator of co-
agulation that has both anticoagulant and anti-
inflammatory effects. Alterations in plasma levels of pro-
tein C, EPCR, or TM that may contribute to decreased
availability of activated protein C are associated with ad-
verse clinical outcomes in patients with ARDS [16, 17].
In the present study, we examined the association of
genetic variation in these protein C pathway genes with
clinical outcomes in patients with ARDS. The results
therefore add to the significance of the previously re-
ported associations of alterations in these protein bio-
marker levels with protein C pathway proteins and
adverse clinical outcomes, and they suggest that genetic
predisposition may play a role in these previously re-
ported associations of abnormalities in protein C path-
way proteins and clinical outcomes in ARDS.
Although we chose a hypothesis-free approach within
the candidate genes, the SNPs that were associated with
adverse clinical outcomes in this study have all previ-
ously been reported (directly or indirectly via a tightly
linked SNP) to have an association with protein levels
and/or clinical outcomes in other conditions. The
rs3176123 SNP in the TM gene is in tight LD with the
rs1042579 SNP (r2 = 1), a coding region nonsynonymous
SNP. The minor allele of this SNP is associated with
increased incidence of venous thrombosis [46, 47]. In
the present study, the minor allele homozygotes had
increased mortality. The GG genotype of the rs1042580
SNP in the TM gene, which was associated with in-
creased mortality in this study, has been associated with
increased cardiovascular disease in females in combin-
ation with factor V Leiden in previous studies [32]. In
our present study, the rs1042580 SNP was associated
with variation in the soluble TM levels in plasma, but
that explained only a minor part of the overall effect of
the SNP on mortality, suggesting that the SNP may have
its effect of through other mechanisms, including the
possibility of altering the functional activity of TM. Fi-
nally, in a previous study, the haplotype tagged by the C
allele of the rs9574 SNP in the EPCR gene was associ-
ated with increased levels of activated protein C levels
and reduced risk of venous thromboembolism [21, 22].
In the present study, we found that the G allele at this
locus is associated with increased mortality. The rs9574
SNP was associated with variation in the soluble EPCR
levels in plasma, but that variation explained only a part
of the overall effect of the SNP on mortality, suggesting
that the SNP may have its effect through other mecha-
nisms, including the possibility that the SNP may have
an additional effect on the functional activity of EPCR.
A novel feature of this study is the combined analysis
of the three genes. In a complex illness such as ARDS,
the impact of genetic factors is likely to be determined
by several variants of small effect size and their possible
interactions. When acting together, these gene variants
may affect the disease outcomes more profoundly than
do the single predisposing variants [32]. An analysis
comprising several genes that belong to the same path-
way may reveal cumulative allelic effects (additive or































Fig. 3 Patients are stratified on the basis of the number of high-risk genotypes possessed by each individual. Results are shown by organ system
(i.e., coagulation [Coag], renal, cardiovascular [Cardio], and central nervous system [CNS]). The y-axis represents the number of organ failure-free
days. There is a stepwise decrease in the number of organ failure-free days with increasing number of high-risk genotypes in all four organ
systems (p values for each system are reported in parentheses along the x-axis)
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individually may have only a modest effect or no meas-
urable impact on clinical outcomes. The combined ana-
lysis of these three proteins is based on the hypothesis
that the three proteins of the protein C pathway act
together to generate the final product (i.e., activated pro-
tein C, which might be the biologically active product
responsible for the clinical effect). Given our a priori
hypothesis that all three genes in this pathway would
have an effect on mortality in patients with ARDS, we
carried out an additional exploratory analysis using the
rs1799810 SNP from the protein C gene based on the
biological role of protein C in the common pathway,
even though this SNP individually had only showed a
trend toward association with increased mortality. Inter-
estingly, the combination of high-risk genotypes from all
three genes in the pathway was associated with mortality
and adverse clinical outcomes upon addition of the pro-
tein C SNP (which was not independently associated
with mortality) to the model.
There are several strengths of our study. These include
the well-characterized clinical phenotype and the multi-
center cohort of patients from a large, well-designed
clinical trial. The previously reported association of clin-
ical outcomes with protein levels and of the coagulation
genes chosen for this study provides the biological
plausibility for the candidate genes chosen for this study.
All the SNPs associated with poor outcomes in ARDS in
our study (or a tightly linked SNP) have been previously
reported to affect protein levels and clinical outcomes in
other populations [19–21, 26, 32, 48]. This finding fur-
ther supports the biological plausibility and increases the
prior probability for the reported associations. This point
is important because genetic association studies with
high prior probability are likely to have a low probability
of reporting false-positive associations [49]. Finally, we
found not only an association of genotypes with mortal-
ity but also a strong association with multiple-organ
failure-free days. This association is significant because
multiorgan failure is the most common attributable
cause of mortality among patients with ARDS [1, 4].
This could be related to the fact that multiorgan failure
and death are associated with each other; alternatively,
the association of the high-risk genotypes with the num-
ber of organ failure-free days may suggest that multior-
gan failure may be an intermediate phenotype, which in
turn leads to the higher mortality associated with the
high-risk genotypes.
This study also has some limitations. First, the results
were obtained only in self-identified white patients of
European ancestry. Second, we did not correct for study-
wide multiple comparisons. Since our hypothesis was
based on the biological plausibility of the three genes in
the protein C pathway and previously reported asso-
ciations with protein levels, we corrected for multiple
comparisons for multiple SNPs tested within each gene
rather than for study-wide multiple comparisons as is the
case with hypothesis-free genome-wide association stud-
ies. Therefore, it is unlikely that these associations were
due to chance alone. However, as is true for all genetic
epidemiology studies, these findings need to be tested and
validated in other patient cohorts.
Conclusions
On the basis of this cohort, the GC/GG genotypes of the
rs9574 SNP in the EPCR gene, as well as the CC geno-
type of rs3716123 and the GG genotype of the rs124580
SNPs in the TM gene, were associated with increased
mortality in adults with ARDS. A combination of these
genotypes had an additive effect on mortality, ventilator-
free days, and organ failure-free days in patients with
ARDS. These findings suggest that genetic differences
may be at least partially responsible for the observed
associations between dysregulated coagulation and poor
outcomes in patients with ARDS. If confirmed, these
findings may support the potential value of testing tar-
geted therapies for ARDS in genetically predisposed
patients.
Additional file
Additional file 1: Figure S1. Patients are stratified on the basis of the
number of high-risk genotypes (four-SNP model) each one possesses,
and the height of the bars represents 60-day mortality in each group
(none 10.3 % [2.2–27.3], n = 29; one 15.2 % [9.9–21.7], n = 158; two 28.5 %
[19.8–38.5], n = 98; three 63.6 % [30.8–89.1], n = 11). There is a stepwise
increase in mortality with increasing number of high-risk genotypes
(p < 0.001). Figure S2 Patients are stratified on the basis of the number
of high-risk genotypes (four-SNP model) each one carries, and the height
of the bars represents the number of ventilator-free days in each group.
There is a stepwise decrease in the number of ventilator-free days with
increasing number of high-risk genotypes (p = 0.01). Figure S3 Patients
are stratified on the basis of the number of high-risk genotypes (four-SNP
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system [CNS]). The y-axis represents the number of organ failure-free
days. There is a stepwise decrease in the number of organ failure-free
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Characteristics of EPCR tag SNPs. Table S3 Characteristics of thrombomodulin
gene tag SNPs. (DOC 1854 kb)
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